Volunteer with EHC
BioMarin announced an additional serious adverse event in its gene therapy clinical trial for haemophilia A
Meet Jeanette Fava, EHC Operations Director
Update on the Recall of Desmopressin Nasal Sprays
The European Haemophilia Consortium (EHC) would like to update its February 2021 statement concerning the international recall of all Ferring Pharmaceutical Limited nasal sprays containing desmopressin, including Octim®, Octostim®, Desmospray®, DDAVP Spray® and Stimate®....
BioMarin follows up on previously-reported serious adverse event in its phase I/II gene therapy clinical trial for haemophilia A
Pfizer/Sangamo Therapeutics report severe adverse event (SAE) from phase 3 AFFINE haemophilia A gene therapy study
Meet Zita Gacser, EHC Think Tank Officer
Announcing: EHC Emergency Displacement Fund (EDF)
With enduring shock and sadness, we think of our community members and others affected by the current challenging times, and are working tirelessly to provide support where possible. The EHC have been working with...